Streetbeat News

Price Targets

OTLY

Barclays analyst Andrew Lazar has maintained an Overweight rating on Oatly Group (NASDAQ:OTLY) but lowered the price target from $3 to $2.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:24 am

HUBG

Barclays analyst Brandon Oglenski maintains an Equal-Weight rating on Hub Group (NASDAQ:HUBG) and raises the price target from $80 to $90.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:23 am

AMBP

Barclays analyst Michael Leithead maintains an Overweight rating on Ardagh Metal Packaging (NYSE:AMBP) but lowers the price target from $6 to $5.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:21 am

BSX

Barclays analyst Matt Miksic maintains an Overweight rating on Boston Scientific (NYSE:BSX) and raises the price target from $56 to $59.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:20 am

CHTR

Barclays analyst Kannan Venkateshwar has maintained an Underweight rating on Charter Communications (NASDAQ:CHTR) and raised the price target from $273 to $325.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:16 am

MDNA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:16 am

AQST

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:15 am

CMCSA

Barclays analyst Kannan Venkateshwar has maintained an Equal-Weight rating on Comcast (NASDAQ:CMCSA) and raised the price target from $42 to $47.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:15 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $51.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 10:14 am

DXCM

Barclays analyst Matt Miksic maintains an Equal-Weight rating on DexCom (NASDAQ:DXCM) and raises the price target from $115 to $138.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 31, 2023 | 10:14 am